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The structural proteins and enzymes of the human immunodeficiency virus type 1 core are translated as part
of two polyprotein precursors, Gag and Gag-Pol, which are cleaved by a virally encoded protease. Viruses grown
in the presence of inhibitors of the protease contain core particles that are aberrantly assembled, and upon
infection of susceptible cells, they do not synthesize viral DNA. Through the use of a proteinase inhibitor
(A77003), we determined that the viral reverse transcriptase can efficiently synthesize viral DNA as part of the
unprocessed Gag-Pol precursor. We also found that the stabilities of core particles composed of unprocessed
precursors were considerably enhanced. These observations suggest that for viruses composed of unprocessed
precursors, replication is interrupted before the reverse transcription step.
The core particle of human immunodeficiency virus type 1
(HIV-1) is assembled from polyprotein precursors which are
cleaved by a virally encoded protease. The viral genome
encodes two of these precursors, Gag and Gag-Pol. When
processed, Gag gives rise to the structural proteins of the core.
The enzymatic proteins of the core are contained in Gag-Pol;
these include the viral protease, the reverse transcriptase (RT),
and the integrase (5). The unprocessed precursors assemble at
the membrane of the infected cell, and proteolytic processing
of Gag and Gag-Pol is initiated during virus assembly.
Mutations which render the protease inactive have been
introduced into several retroviruses including HIV-1 (6, 13,
18), Mason-Pfizer monkey virus (19), Moloney murine leuke-
mia virus (M-MuLV) (4, 11), and Rous sarcoma virus (RSV)
(20). Although virus particles are produced in the absence of
protease activity, complete and accurate processing of these
precursors is required to produce fully infectious virus. If
protease activity is inhibited or absent, the virions produced
are noninfectious and contain aberrantly assembled core par-
ticles (4, 6, 10, 11, 13, 18, 20). Electron micrographic evalua-
tion of the protease-deficient retroviruses indicates that in-
stead of the collapsed, central, electron-dense core seen in
wild-type virus, these particles typically have an abnormal
open, ring-shaped, distended core (6, 10, 11, 18, 20). In
addition, the core particles from the protease-deficient virus
are relatively resistant to nonionic detergents (16a, 20).
It has also been suggested that the viral RT can function as
part of the Gag-Pol precursor. In reactions requiring the
unprocessed RT to act as an RNA-directed DNA polymerase,
the enzyme has been shown to have activity between 15 and
100% that of the wild-type virus (4, 10, 15, 17, 18, 20). For
RSV, Stewart et al. (20) have demonstrated that RT processing
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is required for viral DNA synthesis. In the only other study in
which the endogenous reverse transcription reaction was used
to evaluate the unprocessed RT, Crawford and Goff (4) have
demonstrated that a protease-deficient mutant of M-MuLV
was still able to produce minus-strand strong-stop DNA. This
mutant, however, produced no detectable viral DNA upon
infection of susceptible cells, a finding that we have extended
to HIV-1 using a protease inhibitor and a PCR-based assay to
detect viral DNA (10). In the study described in this report, we
demonstrated that the unprocessed HIV-1 RT can efficiently
reverse transcribe the viral genome in vitro. This indicates that
all of the requirements for reverse transcription can be met by
the full-length Gag and Gag-Pol precursors. Furthermore,
these data suggest that the life cycle of viruses composed of
unprocessed precursors is interrupted before the reverse tran-
scription step.
To characterize the virus particles produced in the presence
of a protease inhibitor, we used HIV-1 isolate HIV-1G, which
was obtained from an infected patient (a gift of M. Cloyd and
R. Buckheit). CEM cells were chronically infected with this
isolate as described previously (9). Briefly, 2 x 106 CEM cells
in 200 ,ul of RPMI 1640 containing 10% (vol/vol) fetal calf
serum and 200 RI of HIV-1 stock were placed in a well of a
48-well plate. The cells and virus were incubated at 37°C for 2
h. The cells were then placed in 10 ml of fresh medium. The
cells were pelleted daily and were resuspended in fresh me-
dium. Maximum virus spread as measured by syncytium for-
mation and cell death occurs at about 5 days postinfection.
After 7 days CEM cells which were chronically infected began
to appear. These cells were resuspended daily in fresh medium
and were used for these experiments at 3 weeks after infection,
at which time virus production was maximal. The cells were
grown for 5 days in 9.0 ,IM HIV-1 protease inhibitor, A-77003
(12), and the medium was replaced daily. Virus supernatant
was recovered on day 6. The sample was divided into aliquots,
and the aliquots were frozen. Virus was concentrated by
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ultracentrifugation through a 15% sucrose cushion at 100,000
x g for 1.5 h.
We used the endogenous reverse transcription reaction to
assay the abilities of virus-containing cores composed of un-
processed precursors to reverse transcribe their genomic
RNAs (13a). By quantitating viral DNA synthesis at each of
the steps of the endogenous reaction, we can assess the ability
of the unprocessed RT to carry out RNA-dependent DNA
synthesis as well as DNA-dependent DNA synthesis using the
enzyme's natural template as a substrate. In addition, the
frequency with which template jumping occurs can also be
evaluated. In contrast, the exogenous reaction is limited to
measuring the ability of the enzyme to act as an RNA-
dependent DNA polymerase on a synthetic template.
For the endogenous reaction, filtered virus supernatants
were recovered from chronically infected CEM cells. The virus
was collected by ultracentrifugation through a cushion con-
taining 20% Renograffin-60 (Squibb) and 80% TEN (10 mM
Tris [pH 8.0], 1 mM EDTA, 100 mM NaCl). A portion of
the virus pellet was added to the endogenous reaction mix-
ture which contained final concentrations of 50 mM NaCl,
50 mM Tris (pH 8.0), 10 mM dithiothreitol, 5 mM MgCl2, and
0.1 mM each dATP, dCTP, dGTP, and dTTP. The concentra-
tion of Triton X-100 was varied from 0 to 0.5%. After
incubation at 37°C, the reaction was stopped by the addition of
EDTA and proteinase K. An aliquot of the reaction mixture
was analyzed by PCR as described previously (1, 20, 21).
Different regions of the newly synthesized viral DNA were
amplified with primers specific for the sequences of interest.
The initial products of reverse transcription (R-U5) were
amplified by primers M667-AA55 (25). The region of the
genome encompassing the nef gene was amplified by using
AA943-AA946 (25). LA45-LA24 amplified tat-rev sequences
(1), and plus-strand DNA which has been extended beyond the
primer binding site after the second template switch is identi-
fied by the long terminal repeat (LTR)-gag primers M667-
M661 (25). In order to make certain that the observed
similarity in DNA synthesis was not due to strain differences
between the untreated and protease-deficient virus stocks
(HIVJRCSF and HIVHXB2, respectively), we compared un-
treated virus derived from these stocks directly in the endog-
enous reaction. We found that an equal amount of the two
strains synthesized equivalent amounts of viral DNA and that,
for both viruses, DNA synthesis was maximal at 0.1% Triton
X-100 (data not shown).
HIV-1 particles produced from infected cells grown in the
presence of greater than 3 ,uM A-77003 are composed of
unprocessed Gag and Gag-Pol precursors (8a, 10). We recov-
ered supernatant from CEM cells chronically infected with
HIV-1 that were maintained either in the presence or the
absence of 9 p,M A-77003 as described above. Virus was
concentrated by ultracentrifugation, and the virion proteins
were subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis. The extent of processing of the Gag and
Gag-Pol precursors was evaluated by Western blot (immuno-
blot) analysis and is shown in Fig. 1. Virus produced by
the untreated cells contained only completely processed pro-
teins. This could be seen when the Western blots were
analyzed for Gag processing by staining with a monoclonal
antibody directed against the mature capsid protein p24 (lane
1). When these samples were stained with a monoclonal
antibody to the RT, only the two forms of the completely
processed mature enzyme (p66 and pS1) were seen (lane
3). However, when chronically infected cells grown in the
presence of 9.0 ,uM inhibitor were evaluated, Gag was pre-








FIG. 1. Processing of Gag and Gag-Pol precursors in the presence
of A-77003. Virus produced either in the presence (lanes 2 and 4) or
the absence (lanes 1 and 3) of A-77003 was collected by ultracentrif-
ugation and was subjected to Western blot analysis. The total amounts
of viral proteins added to each lane were normalized by using serial,
threefold dilutions of each sample. The samples were then stained with
monoclonal antibodies directed against either the p24 capsid protein
(lanes 1 and 2) or the RT (lanes 3 and 4). Molecular weight markers
(in thousands) are shown.
41-kDa processing intermediates (lane 2). A Western blot of
the same sample stained with the monoclonal antibody to
the RT did not reveal any processed enzyme (lane 4). As we
have demonstrated previously (10), this antibody does not
recognize the RT as part of the unprocessed Gag-Pol precur-
sor.
We next characterized the process of reverse transcription in
virus grown in the presence of the inhibitor. Varying results
have been obtained by an exogenous template-based assay to
measure the activity of the RT in viruses composed of unproc-
essed precursors (4, 10, 15, 17, 18, 20). We therefore decided
to use the endogenous reverse transcription reaction in order
to assay the abilities of these viruses to synthesize DNA.
Pelleted samples of virus grown in treated and untreated cells
were normalized for p24 antigen content and were prepared
for the reaction as described above. Three microliters of
pelleted virus containing 750 pg of p24 was used in each
reaction mixture. The ability of the p24 antigen enzyme-linked
immunosorbent assay to measure the capsid protein as part of
the Gag precursor was verified by comparing Western blots of
serial dilutions of both samples (data not shown). Using PCR
primers specific for different parts of the HIV-1 genome, we
were able to distinguish between viral DNA which represents
the initiation of reverse transcription (Fig. 2, R-U5 primers),
the first template switch (nef primers), extension of DNA
synthesis after the first template switch (tat-rev primers), and
nearly complete transcripts (LTR-gag primers). Equivalent
amounts of viral DNA were synthesized by the virus grown in
treated and untreated cells at each of the steps of reverse
transcription. Furthermore, with the exception of the initial
products of reverse transcription, viral DNA synthesis was
maximal at 0.01% Triton for both samples and at each of the
steps of reverse transcription. Of note, some DNA synthesis
was apparent in the absence of detergent. This has been
reported previously and may reflect disruption of the virus
particles during specimen collection (2, 3, 21). The initiation of
reverse transcription is less sensitive to detergent in the virus
grown in treated cells. For this product, the amount of viral
DNA synthesized is not affected by concentrations as high as
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FIG. 2. PCR analysis of endogenous reverse transcription reactions. The endogenous reactions were performed as described above. The
reactions were analyzed by using each of the four primer pairs (R-U5, nef, tat-rev, and LTR-gag) in the presence of EDTA (25 mM) or at various
concentrations of Triton X-100. Endogenous reaction products derived from virus produced in the absence (JRCSF) and the presence (HXB2/I)
of A-77003 were analyzed. EDTA at 250 mM was used as a negative control (lane E). This was diluted to 0.8 mM in the final PCR.
It has been demonstrated that although the retrovirus core
particle is extremely susceptible to low concentrations of
nonionic detergents, a mutation at the protease active site
results in the production of virus particles whose cores are
relatively resistant to detergent (16a, 20). We extended this
observation to HIV-1 treated with protease inhibitors by
determining the stabilities of viral cores that are composed of
unprocessed precursors. p24 antigen determinations were per-
formed on virus supernatants produced by cells infected with
the HIVHXB2 strain and grown either in the presence or the
absence of A-77003. The samples were divided into four equal
aliquots. These supernatant samples were placed at 37°C for 1
h at concentrations of either 0.005, 0.01, or 0.1% Triton X-100
or without detergent. The intact core particles were collected
by ultracentrifugation through a sucrose cushion and were
resuspended in RIPA buffer. The amount of pelletable p24
antigen present in the sample incubated without detergent was
set equal to 100% (Fig. 3). For the virus grown in untreated
CEM cells, greater than 95% of the p24 protein was solubilized
at detergent concentrations of as low as 0.005%. In contrast,
the sample containing unprocessed core precursors was much
less susceptible to the effects of the detergent; one-third of the
viral core proteins were recovered by centrifugation at a
detergent concentration of 0.1%.
Inhibitors of the HIV-1 protease have been developed and
are entering clinical trials (7, 12, 1Sa, 22, 23). Although it has
been well-established that protease-deficient retroviruses are
noninfectious and are aberrantly assembled, the mechanism
behind their loss of infectivity remains obscure. Our data
indicate that virions composed of unprocessed Gag and Gag-
Pol precursors are capable of efficiently synthesizing viral
DNA. On the basis of an estimate of 2 x 106 virions per ng of
p24, we find that both protease-deficient and untreated viruses
produce about one copy of DNA per 10 to 100 virions (14).
This compares favorably with the very low ratio of infectious to
noninfectious HIV-1 particles (e.g., one infectious unit for
every 104 to 107 particles) (14). In addition to demonstrating
the ability of the RT to function as part of the precursor, our
data and those of other investigators (4, 1Sa) also suggest that
the precursors are able to package and anneal the tRNA
primer required for reverse transcription. It is possible that
processing of the RT may have occurred at a level below that
which can be visualized by Western blot analysis. Since com-
parable amounts of viral DNA were synthesized in both the
treated and the untreated virus samples, it is unlikely that the
few virions that may contain a small amount of processed RT
in the protease-deficient virus sample could account for our
results. In order to make certain that the conditions of the
reaction did not result in the release of protease inhibition, we
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FIG. 3. Stability of untreated and protease-inhibited virus to disruption by a nonionic detergent. Virus produced in the absence (A) and the
presence (B) of A-77003 were treated with the indicated concentrations of Triton X-100. The insoluble fraction was recovered by ultracentrifu-
gation. The percentage of p24 antigen recovered is indicated by the bars; the amount recovered without detergent treatment is set equal to 100%.
processing in both the treated and the untreated virus stocks by
Western blot analysis. No additional processing of the viral
core proteins was observed after the reaction (data not shown).
Previous studies have failed to demonstrate the synthesis of
viral DNA upon infection of susceptible cells with protease-
deficient retroviruses (4, 10). Viral replication, therefore, is
blocked at an early step in the life cycle. Since the RT is
functional as part of the unprocessed Gag-Pol precursor, the
lack of viral DNA synthesis after infection may be due to
some difference between the conditions of the endogenous
reaction and the intracellular environment in which reverse
transcription occurs. As we have noted, viruses grown in
the presence of the inhibitor are considerably more stable
than viruses grown in untreated cells. In the endogenous
reaction, the RT must have access to nucleotides, and there-
fore, some disruption of the virus particle by detergent is
required. During infection, the viral core must also allow
nucleotides access to the nucleoprotein replication complex.
The enhanced stability of the core particles composed of
unprocessed precursors may impede uncoating of the core
once it has entered the target cell. Alternatively, the block to
infection may be due to the inability of the core to arrive at a
site within the target cell at which reverse transcription can
proceed. For example, if virions composed of unprocessed
precursors are unable to fuse efficiently with the membrane of
the target cell, viral DNA synthesis would not occur. We are
evaluating whether the presence of unprocessed Gag and
Gag-Pol precursors interferes with this early step in the virus
life cycle. Furthermore, we are using microinjection techniques
to determine whether, once inside a susceptible cell, viral DNA
synthesis can proceed.
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